Retrotope Announces Initiation of Phase 2 Study of RT001 in Patients with Amyotrophic Lateral Sclerosis (ALS)
March 17, 2021 07:00 ET
|
Retrotope
LOS ALTOS, Calif., March 17, 2021 (GLOBE NEWSWIRE) -- Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases,...
Annovis Bio, Inc. to present at the Q1 Virtual Investor Summit
March 11, 2021 07:05 ET
|
Annovis Bio, Inc.
BERWYN, Pa., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Annovis Bio, Inc., ANVS, today announced that Maria Maccecchini, PhD, Founder, President and CEO, will be attending the Q1 Virtual...
Recro to Present at H.C. Wainwright Global Life Science Conference
March 02, 2021 07:00 ET
|
Recro Pharma, Inc.
MALVERN, Pa., March 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Recro Reports Fourth Quarter and Year End 2020 Financial Results
February 26, 2021 07:00 ET
|
Recro Pharma, Inc.
Strengthened Industry-Centric Leadership Reorganization Initiated to Enhance Operations as Recro Expands Customer Portfolio, Explores Inorganic Growth Opportunities Core Commercial Product Outlook...
Recro to Report Fourth Quarter and Year-End 2020 Financial Results Earlier Than Previously Announced
February 23, 2021 16:05 ET
|
Recro Pharma, Inc.
MALVERN, Pa., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Recro Announces Amendment to Athyrium Credit Facility
February 23, 2021 07:00 ET
|
Recro Pharma, Inc.
MALVERN, Pa., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Avid Bioservices Begins Phase 2 of its Myford Manufacturing Capacity Expansion Plan
February 22, 2021 08:05 ET
|
Avid Bioservices, Inc
Build Out of Myford Facility Will Expand Current Footprint to Include Second Manufacturing Train with Both Upstream and Downstream Processing Suites Phase 2 Has Potential to Increase Annual Revenue...
Recro to Report Financial Results for Fourth Quarter And Year-End 2020 on February 26
February 19, 2021 16:05 ET
|
Recro Pharma, Inc.
MALVERN, Pa., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Recro Strengthens Leadership Team With Key Executive and Board Appointments
February 11, 2021 07:00 ET
|
Recro Pharma, Inc.
Company Names CDMO Industry Thought Leader, Jim Miller, to Board of Directors and Selects Ryan D. Lake as Dedicated Chief Financial OfficerRecent Appointments, including CEO David Enloe, Provide...
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
February 08, 2021 16:01 ET
|
Revolution Medicines, Inc.
Underwriters’ Full Exercise of Option Brings Gross Proceeds to $300 Million REDWOOD CITY, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD) today announced the...